
Leonard B Saltz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1606570/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	lrinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer. New England Journal of Medicine, 2000, 343, 905-914.	27.0	2,871
2	Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. Journal of Clinical Oncology, 2008, 26, 2013-2019.	1.6	2,735
3	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	21.4	2,702
4	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	30.7	2,473
5	Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor. Journal of Clinical Oncology, 2004, 22, 1201-1208.	1.6	1,663
6	OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017, 2017, 1-16.	3.0	1,266
7	Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology, 2006, 24, 4293-4300.	1.6	1,144
8	Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry. Journal of Clinical Oncology, 2005, 23, 1803-1810.	1.6	1,050
9	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. Journal of Clinical Oncology, 2015, 33, 2563-2577.	1.6	783
10	Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 2006-2012.	1.6	767
11	Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 329-359.	4.9	758
12	Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 370-398.	4.9	707
13	Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 874-901.	4.9	698
14	NCCN Guidelines Insights: Colon Cancer, Version 2.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 359-369.	4.9	675
15	Impact of Physical Activity on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803. Journal of Clinical Oncology, 2006, 24, 3535-3541.	1.6	664
16	Hepatic neuroendocrine metastases: does intervention alter outcomes?1. Journal of the American College of Surgeons, 2000, 190, 432-445.	0.5	589
17	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer Cell, 2018, 33, 125-136.e3.	16.8	589
18	PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. New England Journal of Medicine, 2022, 386, 2363-2376.	27.0	588

#	Article	IF	CITATIONS
19	Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer. Journal of Clinical Oncology, 2015, 33, 4032-4038.	1.6	583
20	Developing a cancer-specific geriatric assessment. Cancer, 2005, 104, 1998-2005.	4.1	541
21	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. Journal of Clinical Oncology, 2016, 34, 2925-2934.	1.6	538
22	Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?. Journal of Clinical Oncology, 2005, 23, 5235-5246.	1.6	476
23	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncology, The, 2016, 17, 1709-1719.	10.7	442
24	Irinotecan Fluorouracil Plus Leucovorin Is Not Superior to Fluorouracil Plus Leucovorin Alone As Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803. Journal of Clinical Oncology, 2007, 25, 3456-3461.	1.6	423
25	Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma. JAMA - Journal of the American Medical Association, 2010, 304, 2154.	7.4	412
26	Colon Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 778-831.	4.9	409
27	Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study. Journal of Clinical Oncology, 2007, 25, 4557-4561.	1.6	406
28	Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncology, 2018, 4, e180071.	7.1	404
29	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal of Clinical Oncology, 2019, 37, 286-295.	1.6	397
30	Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2015, 107, .	6.3	385
31	Neoadjuvant Chemotherapy Without Routine Use of Radiation Therapy for Patients With Locally Advanced Rectal Cancer: A Pilot Trial. Journal of Clinical Oncology, 2014, 32, 513-518.	1.6	375
32	Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment. Journal of Clinical Oncology, 2009, 27, 3379-3384.	1.6	370
33	The camptothecins. Lancet, The, 2003, 361, 2235-2242.	13.7	369
34	Association of Dietary Patterns With Cancer Recurrence and Survival in Patients With Stage III Colon Cancer. JAMA - Journal of the American Medical Association, 2007, 298, 754.	7.4	369
35	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA - Journal of the American Medical Association, 2017, 318, 825.	7.4	366
36	Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome. Journal of Clinical Oncology, 1999, 17, 600-600.	1.6	358

#	Article	IF	CITATIONS
37	Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. Clinical Cancer Research, 2018, 24, 4154-4161.	7.0	348
38	Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. JAMA Oncology, 2019, 5, e185896.	7.1	347
39	Assessing The Predictive Value of Clinical Complete Response To Neoadjuvant Therapy for Rectal Cancer: An Analysis of 488 Patients. Journal of the American College of Surgeons, 2002, 194, 131-135.	0.5	342
40	Long-term Oncologic Outcome Following Preoperative Combined Modality Therapy and Total Mesorectal Excision of Locally Advanced Rectal Cancer. Annals of Surgery, 2005, 241, 829-838.	4.2	341
41	Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803. Journal of Clinical Oncology, 2009, 27, 1814-1821.	1.6	333
42	Nonoperative Management of Rectal Cancer With Complete Clinical Response After Neoadjuvant Therapy. Annals of Surgery, 2012, 256, 965-972.	4.2	325
43	A rectal cancer organoid platform to study individual responses to chemoradiation. Nature Medicine, 2019, 25, 1607-1614.	30.7	320
44	NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 806-815.	4.9	310
45	Neuroendocrine Tumors, Version 1.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 78-108.	4.9	302
46	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biology, 2014, 15, 454.	8.8	296
47	Neuroendocrine Carcinomas of the Colon and Rectum. Diseases of the Colon and Rectum, 2004, 47, 163-169.	1.3	293
48	Extracellular Metabolic Energetics Can Promote Cancer Progression. Cell, 2015, 160, 393-406.	28.9	293
49	Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. Journal of Clinical Oncology, 2022, 40, 2546-2556.	1.6	292
50	Rectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 838-881.	4.9	289
51	NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 693-702.	4.9	289
52	Advanced Hepatocellular Carcinoma: Which Staging Systems Best Predict Prognosis?. Journal of Clinical Oncology, 2010, 28, 2889-2895.	1.6	286
53	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clinical Cancer Research, 2018, 24, 1326-1336.	7.0	281
54	Randomized Double-Blind Trial of Prophylactic Oral Minocycline and Topical Tazarotene for Cetuximab-Associated Acne-Like Eruption. Journal of Clinical Oncology, 2007, 25, 5390-5396.	1.6	269

#	Article	IF	CITATIONS
55	Clinical Characteristics and Outcomes From an Institutional Series of Acinar Cell Carcinoma of the Pancreas and Related Tumors. Journal of Clinical Oncology, 2002, 20, 4673-4678.	1.6	268
56	Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer, 1993, 72, 244-248.	4.1	257
57	HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum. Oncologist, 2005, 10, 345-356.	3.7	257
58	Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2010, 28, 3485-3490.	1.6	257
59	Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas. Journal of Clinical Oncology, 2012, 30, 2956-2962.	1.6	254
60	Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esophageal Cancer. Journal of Clinical Oncology, 1999, 17, 3270-3275.	1.6	246
61	Impact of Body Mass Index and Weight Change After Treatment on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From Cancer and Leukemia Group B 89803. Journal of Clinical Oncology, 2008, 26, 4109-4115.	1.6	245
62	Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer. Cancer Research, 2010, 70, 5901-5911.	0.9	245
63	Individualized Prediction of Colon Cancer Recurrence Using a Nomogram. Journal of Clinical Oncology, 2008, 26, 380-385.	1.6	244
64	Long-Term Prognostic Significance of Extent of Rectal Cancer Response to Preoperative Radiation and Chemotherapy. Annals of Surgery, 2002, 236, 75-81.	4.2	240
65	Pilot Trial of Combined BRAF and EGFR Inhibition in <i>BRAF</i> -Mutant Metastatic Colorectal Cancer Patients. Clinical Cancer Research, 2015, 21, 1313-1320.	7.0	240
66	Predictive and Prognostic Roles of <i>BRAF</i> Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803. Clinical Cancer Research, 2012, 18, 890-900.	7.0	239
67	Rate of Pathologic Complete Response With Increased Interval Between Preoperative Combined Modality Therapy and Rectal Cancer Resection. Diseases of the Colon and Rectum, 2004, 47, 279-286.	1.3	234
68	The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Investigational New Drugs, 2008, 26, 45-51.	2.6	234
69	Pathologic stage is most prognostic of diseaseâ€free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer, 2008, 113, 57-64.	4.1	228
70	Adjuvant Chemotherapy Use for Medicare Beneficiaries With Stage II Colon Cancer. Journal of Clinical Oncology, 2002, 20, 3999-4005.	1.6	226
71	Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines. Journal of Clinical Oncology, 2008, 26, 2118-2123.	1.6	226
72	Cetuximab Therapy and Symptomatic Hypomagnesemia. Journal of the National Cancer Institute, 2005, 97, 1221-1224.	6.3	224

#	Article	IF	CITATIONS
73	Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. Diseases of the Colon and Rectum, 1997, 40, 515-522.	1.3	221
74	Irinotecan/Fluorouracil Combination in First-Line Therapy of Older and Younger Patients With Metastatic Colorectal Cancer: Combined Analysis of 2,691 Patients in Randomized Controlled Trials. Journal of Clinical Oncology, 2008, 26, 1443-1451.	1.6	216
75	Use of Surgery Among Elderly Patients With Stage IV Colorectal Cancer. Journal of Clinical Oncology, 2004, 22, 3475-3484.	1.6	213
76	Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database. Journal of Clinical Oncology, 2013, 31, 2600-2606.	1.6	211
77	Adequacy of 1-cm Distal Margin After Restorative Rectal Cancer Resection With Sharp Mesorectal Excision and Preoperative Combined-Modality Therapy. Annals of Surgical Oncology, 2003, 10, 80-85.	1.5	208
78	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. Journal of Clinical Oncology, 2016, 34, 2141-2147.	1.6	204
79	Phase II Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol Administered to Patients With Advanced Gastric Carcinoma. Journal of Clinical Oncology, 2001, 19, 1985-1992.	1.6	198
80	Venous Thromboembolic Events With Chemotherapy Plus Bevacizumab: A Pooled Analysis of Patients in Randomized Phase II and III Studies. Journal of Clinical Oncology, 2011, 29, 1757-1764.	1.6	197
81	Colon Cancer, Version 3.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1028-1059.	4.9	192
82	<i>KRAS</i> Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803. Clinical Cancer Research, 2009, 15, 7322-7329.	7.0	187
83	Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 513-519.	4.9	186
84	XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. British Journal of Cancer, 2011, 105, 58-64.	6.4	184
85	Rectal Cancer, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 719-728.	4.9	181
86	Comparison of Tumor Regression Grade Systems for Locally Advanced Rectal Cancer After Multimodality Treatment. Journal of the National Cancer Institute, 2014, 106, .	6.3	179
87	Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer, 1999, 86, 944-948.	4.1	175
88	Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer1 1No competing interests declared Journal of the American College of Surgeons, 2004, 199, 1-7.	0.5	173
89	Prognostic Factors for Recurrence After Pulmonary Resection of Colorectal Cancer Metastases. Annals of Thoracic Surgery, 2009, 87, 1684-1688.	1.3	170
90	BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer, 2014, 120, 2316-2324.	4.1	170

#	Article	IF	CITATIONS
91	Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. International Journal of Radiation Oncology Biology Physics, 1997, 37, 289-295.	0.8	169
92	Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial Journal of Clinical Oncology, 2020, 38, 4008-4008.	1.6	168
93	Identification of germline genetic mutations in patients with pancreatic cancer. Cancer, 2015, 121, 4382-4388.	4.1	167
94	Is Nonsmall Cell Type High-grade Neuroendocrine Carcinoma of the Tubular Gastrointestinal Tract a Distinct Disease Entity?. American Journal of Surgical Pathology, 2008, 32, 719-731.	3.7	166
95	Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer—A Study of CALGB 9581 and 89803. Journal of Clinical Oncology, 2011, 29, 3153-3162.	1.6	166
96	Dietary Glycemic Load and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings From CALGB 89803. Journal of the National Cancer Institute, 2012, 104, 1702-1711.	6.3	163
97	Clinical Examination Following Preoperative Chemoradiation for Rectal Cancer Is Not a Reliable Surrogate End Point. Journal of Clinical Oncology, 2005, 23, 3475-3479.	1.6	161
98	Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study. Annals of Surgical Oncology, 2007, 14, 759-765.	1.5	161
99	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Clinical Cancer Research, 2017, 23, 6094-6100.	7.0	161
100	Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 1948-1955.	1.6	160
101	Phase I Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination With Paclitaxel in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2002, 20, 2157-2170.	1.6	157
102	Neuroendocrine Tumors. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 724-764.	4.9	157
103	Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Diseases of the Colon and Rectum, 2000, 43, 18-24.	1.3	156
104	Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2001, 49, 987-995.	0.8	155
105	Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. British Journal of Cancer, 2009, 101, 1033-1038.	6.4	154
106	Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials. Journal of Clinical Oncology, 2011, 29, 83-88.	1.6	151
107	ISLET CELL TUMORS OF THE PANCREAS. Surgical Clinics of North America, 2001, 81, 527-542.	1.5	150
108	Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis. JAMA Oncology, 2018, 4, 783.	7.1	147

#	Article	IF	CITATIONS
109	Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Modern Pathology, 2005, 18, 1350-1356.	5.5	146
110	Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome. JAMA Oncology, 2018, 4, 309.	7.1	146
111	Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. Journal of Cancer Research and Clinical Oncology, 2010, 136, 737-743.	2.5	145
112	Neoadjuvant Chemotherapy for Metastatic Colon Cancer: A Cautionary Note. Journal of Clinical Oncology, 2005, 23, 9073-9078.	1.6	143
113	Rectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1528-1564.	4.9	138
114	Phase II Trial of Sunitinib in Patients With Metastatic Colorectal Cancer After Failure of Standard Therapy. Journal of Clinical Oncology, 2007, 25, 4793-4799.	1.6	137
115	L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer. Nature Cancer, 2020, 1, 28-45.	13.2	137
116	FDA Approval of Tisagenlecleucel. JAMA - Journal of the American Medical Association, 2017, 318, 1861.	7.4	136
117	Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors Journal of Clinical Oncology, 1996, 14, 2959-2967.	1.6	132
118	Irinotecan Plus Fluorouracil/Leucovorin for Metastatic Colorectal Cancer: A New Survival Standard. Oncologist, 2001, 6, 81-91.	3.7	131
119	Metastatic Colon Cancer, Version 3.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 141-152.	4.9	130
120	Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2010, 28, 4240-4246.	1.6	129
121	Preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for rectal cancer. Cancer, 1994, 73, 273-280.	4.1	125
122	Surgical Debulking and Intraperitoneal Chemotherapy for Established Peritoneal Metastases From Colon and Appendix Cancer. Annals of Surgical Oncology, 2001, 8, 787-795.	1.5	124
123	Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer. European Radiology, 2012, 22, 821-831.	4.5	121
124	Evolving Treatment of Advanced Colon Cancer. Annual Review of Medicine, 2009, 60, 207-219.	12.2	120
125	Association of Age With Survival in Patients With Metastatic Colorectal Cancer: Analysis From the ARCAD Clinical Trials Program. Journal of Clinical Oncology, 2014, 32, 2975-2982.	1.6	118
126	CpG Island Methylator Phenotype Is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage III Colon Cancer. Gastroenterology, 2014, 147, 637-645.	1.3	118

#	Article	IF	CITATIONS
127	Mismatch Repair–Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. Clinical Cancer Research, 2020, 26, 3271-3279.	7.0	118
128	High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer. International Journal of Radiation Oncology Biology Physics, 2000, 48, 219-226.	0.8	116
129	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. Journal of Clinical Oncology, 2016, 34, 144-150.	1.6	116
130	Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer. Journal of the National Cancer Institute, 2015, 107, 345.	6.3	115
131	Phase I Trial of the Cyclin-Dependent Kinase Inhibitor and Protein Kinase C Inhibitor 7-Hydroxystaurosporine in Combination With Fluorouracil in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2005, 23, 1875-1884.	1.6	113
132	Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. Cancer Research, 2019, 79, 1047-1053.	0.9	112
133	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma. JAMA Oncology, 2020, 6, 60.	7.1	112
134	A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol. Clinical Cancer Research, 2005, 11, 3836-3845.	7.0	109
135	Overspending driven by oversized single dose vials of cancer drugs . BMJ, The, 2016, 352, i788.	6.0	109
136	Abdominoperineal resection for rectal cancer at a specialty center. Diseases of the Colon and Rectum, 2001, 44, 27-35.	1.3	108
137	Oncologic Outcomes of Salvage Surgery for Epidermoid Carcinoma of the Anus Initially Managed With Combined Modality Therapy. Diseases of the Colon and Rectum, 2004, 47, 1136-1144.	1.3	107
138	The efficacy of preoperative 5-fluorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. Cancer, 1993, 71, 3486-3492.	4.1	104
139	Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 852-871.	4.9	104
140	NCCN Task Force Report: Management of Dermatologic and Other Toxicities Associated With EGFR Inhibition in Patients With Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, S-5-S-21.	4.9	102
141	A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. British Journal of Cancer, 2013, 109, 915-919.	6.4	102
142	A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer, 1995, 75, 782-785.	4.1	96
143	Neither FDG-PET Nor CT Can Distinguish Between a Pathological Complete Response and an Incomplete Response After Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. Annals of Surgery, 2013, 258, 289-295.	4.2	94
144	A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Annals of Oncology, 2002, 13, 1067-1071.	1.2	93

#	Article	IF	CITATIONS
145	Unusual DNA mismatch repair–deficient tumors in Lynch syndrome: a report of new cases and review of the literature. Human Pathology, 2012, 43, 1677-1687.	2.0	93
146	Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1109-1133.	4.9	92
147	Metabolic Signatures Associated with a NAD Synthesis Inhibitor–Induced Tumor Apoptosis Identified by 1H-Decoupled-31P Magnetic Resonance Spectroscopy. Clinical Cancer Research, 2005, 11, 3503-3513.	7.0	90
148	Preoperative high-dose leucovorin/5-fluorouracil and radiation therapy for unresectable rectal cancer. Cancer, 1991, 67, 2859-2866.	4.1	87
149	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. Journal of Clinical Oncology, 2015, 33, 22-28.	1.6	87
150	A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. Journal of Hepatology, 2014, 60, 319-324.	3.7	83
151	Localized Colon Cancer, Version 3.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 519-528.	4.9	81
152	False-Positive Elevations of Carcinoembryonic Antigen in Patients With a History of Resected Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 907-913.	4.9	81
153	A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer, 2001, 91, 101-105.	4.1	80
154	Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1363-1370.	0.8	77
155	Squamous Cell Carcinoma of the Anal Canal: Patterns and Predictors of Failure and Implications for Intensity-Modulated Radiation Treatment Planning. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1064-1072.	0.8	77
156	The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer. Annals of Surgical Oncology, 2018, 25, 431-438.	1.5	76
157	Conservative management of rectal cancer with local excision and postoperative adjuvant therapy. International Journal of Radiation Oncology Biology Physics, 1999, 44, 841-846.	0.8	75
158	Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Annals of Oncology, 2011, 22, 2604-2609.	1.2	75
159	A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Annals of Oncology, 2008, 19, 86-91.	1.2	72
160	SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance. Clinical Cancer Research, 2019, 25, 1948-1956.	7.0	71
161	Complications after Preoperative Combined Modality Therapy and Radical Resection of Locally Advanced Rectal Cancer: A 14-Year Experience from a Specialty Service. Journal of the American College of Surgeons, 2005, 200, 876-882.	0.5	70
162	Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803. Journal of the National Cancer Institute, 2011, 103, 1540-1551.	6.3	69

#	Article	IF	CITATIONS
163	Association of Family History With Cancer Recurrence and Survival Among Patients With Stage III Colon Cancer. JAMA - Journal of the American Medical Association, 2008, 299, 2515.	7.4	67
164	Anal Carcinoma, Version 2.2012. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 449-454.	4.9	67
165	Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer. Clinical Colorectal Cancer, 2012, 11, 101-111.	2.3	67
166	End Points in Advanced Colon Cancer Clinical Trials: A Review and Proposal. Journal of Clinical Oncology, 2007, 25, 3572-3575.	1.6	66
167	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. Journal of the National Cancer Institute, 2021, 113, 1683-1692.	6.3	66
168	Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. Annals of Surgical Oncology, 2002, 9, 954-960.	1.5	65
169	Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance). PLoS ONE, 2014, 9, e99816.	2.5	65
170	A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer, 1994, 74, 958-961.	4.1	64
171	Anal Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 106-120.	4.9	64
172	Pulmonary Recurrence Predominates After Combined Modality Therapy for Rectal Cancer. Annals of Surgery, 2012, 256, 111-116.	4.2	63
173	Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters. European Radiology, 2016, 26, 4303-4312.	4.5	63
174	Panitumumab. Nature Reviews Drug Discovery, 2006, 5, 987-988.	46.4	62
175	Palliative Care in the Outpatient Oncology Setting: Evaluation of a Practical Set of Referral Criteria. Journal of Oncology Practice, 2011, 7, 366-370.	2.5	62
176	ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.3	62
177	Coaltered <i>Ras/B-raf</i> and <i>TP53</i> Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2020, 26, 1077-1085.	7.0	62
178	A prospective randomized trial of topical pimecrolimus for cetuximab-associated acne-like eruption. Journal of the American Academy of Dermatology, 2009, 61, 614-620.	1.2	61
179	Outcomes Among Black Patients With Stage II and III Colon Cancer Receiving Chemotherapy: An Analysis of ACCENT Adjuvant Trials. Journal of the National Cancer Institute, 2011, 103, 1498-1506.	6.3	61
180	Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). Journal of Clinical Oncology, 2015, 33, 3598-3607.	1.6	60

#	Article	IF	CITATIONS
181	PKLR promotes colorectal cancer liver colonization through induction of glutathione synthesis. Journal of Clinical Investigation, 2016, 126, 681-694.	8.2	60
182	A phase 2 study of the insulinâ€like growth factorâ€l receptor inhibitor MKâ€0646 in patients with metastatic, wellâ€differentiated neuroendocrine tumors. Cancer, 2012, 118, 4795-4800.	4.1	59
183	PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis. ELife, 2019, 8, .	6.0	59
184	Pre-operative combined 5-FU, low dose leucovorin, and sequential radiation therapy for unresectable recta cancer. International Journal of Radiation Oncology Biology Physics, 1993, 25, 821-827.	0.8	58
185	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Cancer Research, 2017, 77, 6513-6523.	0.9	58
186	Impact of smoking on patients with stage III colon cancer. Cancer, 2010, 116, 957-966.	4.1	57
187	Adjuvant Therapy of Colon Cancer: Current Status and Future Directions. Cancer Journal (Sudbury,) Tj ETQq1 1 C).784314 2.0	rgBT /Overlo
188	Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations. Clinical Cancer Research, 2017, 23, 4753-4760.	7.0	56
189	Bevacizumab 5 mg/kg Can Be Infused Safely Over 10 Minutes. Journal of Clinical Oncology, 2007, 25, 2691-2695.	1.6	54
190	Pathologic Response to Preoperative Chemotherapy in Colorectal Liver Metastases: Fibrosis, not Necrosis, Predicts Outcome. Annals of Surgical Oncology, 2012, 19, 2797-2804.	1.5	53
191	TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for firstâ€line treatment of metastatic colorectal cancer. Cancer, 2013, 119, 4290-4298.	4.1	53
192	Primary Adenocarcinoma of the Anus Treated With Combined Modality Therapy. Diseases of the Colon and Rectum, 2003, 46, 1320-1324.	1.3	52
193	Marine ω-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 438-445.	2.5	52
194	Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance). Clinical Trials, 2019, 16, 165-175.	1.6	52
195	Colon Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 1238-1290.	4.9	52
196	Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 2200-2208.	7.0	51
197	Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients Journal of Clinical Oncology, 2016, 34, 3539-3539.	1.6	51
198	Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). Journal of Clinical Oncology, 2018, 36, 1112-1120.	1.6	50

#	Article	IF	CITATIONS
199	Pharmacogenomic Modeling of Circulating Tumor and Invasive Cells for Prediction of Chemotherapy Response and Resistance in Pancreatic Cancer. Clinical Cancer Research, 2014, 20, 5281-5289.	7.0	49
200	Colon Cancer Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2003, 1, 40.	4.9	49
201	Distal cT2N0 Rectal Cancer: Is There an Alternative to Abdominoperineal Resection?. Journal of Clinical Oncology, 2005, 23, 4905-4912.	1.6	48
202	Adjuvant therapy for colorectal cancer. Current Problems in Surgery, 1997, 34, 601-676.	1.1	47
203	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. Molecular Cancer Research, 2016, 14, 296-301.	3.4	46
204	Perspectives on Cost and Value in Cancer Care. JAMA Oncology, 2016, 2, 19.	7.1	44
205	Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1087-1095.	0.8	44
206	Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. Journal of the National Cancer Institute, 2021, 113, 400-407.	6.3	44
207	Adjuvant therapy of cancers of the colon and rectum. Surgical Clinics of North America, 2002, 82, 1035-1058.	1.5	43
208	Predictive and Prognostic Analysis of PIK3CA Mutation in Stage III Colon Cancer Intergroup Trial. Journal of the National Cancer Institute, 2013, 105, 1789-1798.	6.3	43
209	Clinical and genetic determinants of ovarian metastases from colorectal cancer. Cancer, 2017, 123, 1134-1143.	4.1	43
210	Antibodyâ€Based Therapies for Colorectal Cancer. Oncologist, 2005, 10, 701-709.	3.7	42
211	A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer. Cancer, 1994, 74, 2224-2233.	4.1	41
212	Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors Journal of Clinical Oncology, 1998, 16, 3858-3865.	1.6	41
213	Occult Primary. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 1358-1395.	4.9	41
214	Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: A propensity score analysis. Radiotherapy and Oncology, 2013, 107, 189-194.	0.6	41
215	Serum 25-Hydroxy Vitamin D and Survival in Advanced Colorectal Cancer: A Retrospective Analysis. Nutrition and Cancer, 2015, 67, 424-430.	2.0	41
216	Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 50-58.	4.9	41

#	Article	IF	CITATIONS
217	Progress in Cancer Care: The Hope, the Hype, and the Gap Between Reality and Perception. Journal of Clinical Oncology, 2008, 26, 5020-5021.	1.6	40
218	Multivitamin Use Is Not Associated With Cancer Recurrence or Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803. Journal of Clinical Oncology, 2010, 28, 4354-4363.	1.6	40
219	Recurrence Rates and Prognostic Factors in ypN0 Rectal Cancer After Neoadjuvant Chemoradiation and Total Mesorectal Excision. Annals of Surgical Oncology, 2011, 18, 3666-3672.	1.5	40
220	Association of <i>TP53</i> Mutational Status and Gender with Survival after Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803. Clinical Cancer Research, 2013, 19, 5777-5787.	7.0	40
221	A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. Annals of Oncology, 2001, 12, 501-504.	1.2	39
222	Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma—A New Look at an Old Drug. Oncologist, 2017, 22, 1102-1106.	3.7	39
223	Study Using the NCCN Guidelines for Palliative Care to Screen Patients for Palliative Care Needs and Referral to Palliative Care Specialists. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1087-1096.	4.9	38
224	Epidermal Growth Factor Receptor—Negative Colorectal Cancer: Is There Truly Such an Entity?. Clinical Colorectal Cancer, 2005, 5, S98-S100.	2.3	37
225	Ganetespib, a Novel Hsp90 Inhibitor in Patients With KRAS Mutated and Wild Type, Refractory Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2014, 13, 207-212.	2.3	37
226	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. Journal of Clinical Oncology, 2017, 35, 1929-1937.	1.6	37
227	How Should We Intervene on the Financial Toxicity of Cancer Care? One Shot, Four Perspectives. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 35-39.	3.8	35
228	New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. Lancet Oncology, The, 2001, 2, 290-297.	10.7	34
229	Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. Cancer, 2006, 106, 1857-1862.	4.1	34
230	Evaluation of 18F-FDG-PET for Early Detection of Suboptimal Response of Rectal Cancer to Preoperative Chemoradiotherapy: A Prospective Analysis. Annals of Surgical Oncology, 2011, 18, 2783-2789.	1.5	34
231	Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer. Journal of Clinical Oncology, 2021, 39, 911-919.	1.6	34
232	Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. Cancer, 2012, 118, 5414-5423.	4.1	33
233	Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors. Investigational New Drugs, 2015, 33, 1086-1092.	2.6	33
234	Management of Locally Advanced Rectal Cancer During The COVID-19 Pandemic: A Necessary Paradigm Change at Memorial Sloan Kettering Cancer Center. Advances in Radiation Oncology, 2020, 5, 687-689.	1.2	33

#	Article	IF	CITATIONS
235	Oral Chemotherapeutic Agents for Colorectal Cancer. Oncologist, 2000, 5, 99-107.	3.7	32
236	Safe and Cost Effective Use of Alteplase for the Clearance of Occluded Central Venous Access Devices. Journal of Clinical Oncology, 2002, 20, 1918-1922.	1.6	32
237	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. Journal of Clinical Oncology, 2016, 34, 1182-1189.	1.6	32
238	Adjuvant therapy for colorectal cancer. Current Problems in Cancer, 1998, 22, 11-77.	2.0	31
239	ACCO: ASCO Core Curriculum Outline. Journal of Clinical Oncology, 2005, 23, 2049-2077.	1.6	31
240	Impact of Physical Activity After Cancer Diagnosis on Survival in Patients With Recurrent Colon Cancer: Findings From CALGB 89803/Alliance. Clinical Colorectal Cancer, 2013, 12, 233-238.	2.3	31
241	Incidence of Chemotherapy-Induced Amenorrhea in Premenopausal Women Treated With AdjuvantÂFOLFOX for Colorectal Cancer. Clinical Colorectal Cancer, 2013, 12, 163-167.	2.3	31
242	Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). Anticancer Research, 2010, 30, 4209-17.	1.1	30
243	9-aminocamptothecin by 72-hour continuous intravenous infusion is Inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma. , 1997, 80, 1727-1732.		29
244	A Phase II Trial of Interferon Alpha-2a and Carboplatin in Patients with Advanced Malignant Mesothelioma. Cancer Investigation, 1999, 17, 195-200.	1.3	29
245	Surgery and High-Dose-Rate Intraoperative Radiation Therapy for Recurrent Squamous-Cell Carcinoma of the Anal Canal. Diseases of the Colon and Rectum, 2011, 54, 1090-1097.	1.3	29
246	A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer. Clinical Colorectal Cancer, 2016, 15, 222-227.	2.3	29
247	Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19. JAMA Oncology, 2020, 6, 1694.	7.1	29
248	A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma. Cancer, 1995, 75, 2197-2202.	4.1	28
249	Addition of Octreotide Functional Imaging to Cross-Sectional Computed Tomography or Magnetic Resonance Imaging for the Detection of Neuroendocrine Tumors: Added Value or an Anachronism?. Journal of Clinical Oncology, 2011, 29, e74-e75.	1.6	28
250	Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. Modern Pathology, 2019, 32, 110-121.	5.5	28
251	Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. Journal of Clinical Oncology, 2021, 39, 950-955.	1.6	28
252	Adjuvant Therapy for Colon Cancer. Surgical Oncology Clinics of North America, 2010, 19, 819-827.	1.5	27

#	Article	IF	CITATIONS
253	Occult Primary, Version 3.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 969-974.	4.9	27
254	Adjuvant Therapy of Colorectal Cancer. Surgical Oncology Clinics of North America, 1997, 6, 699-722.	1.5	26
255	FDG-PET Assessment of Rectal Cancer Response to Neoadjuvant Chemoradiotherapy Is Not Associated With Long-Term Prognosis. Diseases of the Colon and Rectum, 2012, 55, 378-386.	1.3	26
256	The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. Journal of the National Cancer Institute, 2018, 110, 888-894.	6.3	26
257	Phase II trial of gemcitabine in patients with advanced gastric cancer. Cancer, 1994, 73, 5-7.	4.1	25
258	Colorectal Cancer Survivors' Needs and Preferences for Survivorship Information. Journal of Oncology Practice, 2014, 10, e277-e282.	2.5	25
259	The Value of Considering Cost, and the Cost of Not Considering Value. Journal of Clinical Oncology, 2016, 34, 659-660.	1.6	25
260	Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS ONE, 2018, 13, e0199244.	2.5	25
261	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. Journal of the National Cancer Institute, 2021, 113, 1693-1704.	6.3	25
262	Colorectal cancer patients with oligometastatic liver disease: what is the optimal approach?. Oncology, 2013, 27, 1074-8.	0.5	25
263	A phase II trial of carboplatin in patients with advanced APUD tumors. Cancer, 1993, 72, 619-622.	4.1	24
264	Expression of p27 in Residual Rectal Cancer after Preoperative Chemoradiation Predicts Long-term Outcome. Annals of Surgical Oncology, 2004, 11, 955-961.	1.5	24
265	Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. Nature Reviews Clinical Oncology, 2009, 6, 143-152.	27.6	24
266	Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival. Molecular Cancer Research, 2017, 15, 708-713.	3.4	24
267	Understanding and managing chemotherapy-induced diarrhea. The Journal of Supportive Oncology, 2003, 1, 35-46; discussion 38-41, 45-6.	2.3	24
268	Goblet cell carcinoid neoplasm of the appendix: Clinical and CT features. European Journal of Radiology, 2013, 82, 85-89.	2.6	23
269	Characterization and Clinical Outcomes of DNA Mismatch Repair–deficient Small Bowel Adenocarcinoma. Clinical Cancer Research, 2021, 27, 1429-1437.	7.0	23
270	Phase i trial of postoperative 5-FU, radiation therapy, and high dose leucovorin for resectable rectal cancer. International Journal of Radiation Oncology Biology Physics, 1992, 22, 139-145.	0.8	22

#	Article	IF	CITATIONS
271	Lymph Node Metastasis Predicts Disease Recurrence in a Single-Center Experience of 70 Stages 1–3 Appendix Cancers: A Retrospective Review. Annals of Surgical Oncology, 2015, 22, 3613-3617.	1.5	22
272	Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. Cancer, 1995, 75, 769-774.	4.1	21
273	ADJUVANT TREATMENT OF COLORECTAL CANCER. Annual Review of Medicine, 1997, 48, 191-202.	12.2	21
274	Systemic Therapy for Colon Cancer. Gastroenterology Clinics of North America, 2008, 37, 287-295.	2.2	21
275	Can Money Really Be No Object When Cancer Care Is the Subject?. Journal of Clinical Oncology, 2015, 33, 1093-1094.	1.6	21
276	FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer. Clinical Colorectal Cancer, 2019, 18, e39-e52.	2.3	21
277	Diet- and Lifestyleâ€Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). Journal of Clinical Oncology, 2022, 40, 740-751.	1.6	20
278	Frequency, Characteristics, and Correlates of Pain in a Pilot Study of Colorectal Cancer Survivors 1–10 Years Post-Treatment. Pain Medicine, 2013, 14, 1673-1680.	1.9	19
279	Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. British Journal of Cancer, 2018, 119, 1451-1455.	6.4	19
280	Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). Journal of the National Cancer Institute, 2019, 111, 170-179.	6.3	19
281	MicroRNA-203 predicts human survival after resection of colorectal liver metastasis. Oncotarget, 2017, 8, 18821-18831.	1.8	19
282	Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations. Familial Cancer, 2017, 16, 525-529.	1.9	18
283	Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Oncologist, 2017, 22, 780-e65.	3.7	18
284	A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. Oncologist, 2017, 22, 107-114.	3.7	18
285	Current management of advanced hepatocellular carcinoma. Gastrointestinal Cancer Research: GCR, 2008, 2, 64-70.	0.7	18
286	Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. Annals of Oncology, 2002, 13, 1490-1496.	1.2	17
287	Comparison of Dietary and Lifestyle Habits Among Stage III and Metastatic Colorectal Cancer Patients: Findings from CALGB 89803 and CALGB 80405. Clinical Colorectal Cancer, 2013, 12, 95-102.	2.3	17
288	MRE11-Deficiency Associated with Improved Long-Term Disease Free Survival and Overall Survival in a Subset of Stage III Colon Cancer Patients in Randomized CALGB 89803 Trial. PLoS ONE, 2014, 9, e108483.	2.5	17

#	Article	IF	CITATIONS
289	Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. European Journal of Cancer, 2019, 111, 82-93.	2.8	17
290	Evolving Treatment of Advanced Colorectal Cancer. Current Oncology Reports, 2010, 12, 153-159.	4.0	16
291	<i>KRAS</i> and Colorectal Cancer: Ethical and Pragmatic Issues in Effecting Real-Time Change in Oncology Clinical Trials and Practice. Oncologist, 2011, 16, 1061-1068.	3.7	16
292	Contemporary Validation of a Nomogram Predicting Colon Cancer Recurrence, Revealing All-Stage Improved Outcomes. JNCI Cancer Spectrum, 2019, 3, pkz015.	2.9	16
293	Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery. JAMA Network Open, 2021, 4, e2133457.	5.9	16
294	Metastatic colorectal cancer: is there one standard approach?. Oncology, 2005, 19, 1147-54; discussion 1154, 1157-8, 1160.	0.5	16
295	lrinotecan (Campto®) in the treatment of pancreatic cancer. Expert Review of Anticancer Therapy, 2003, 3, 587-593.	2.4	15
296	Ten-Year Results of Preoperative Radiation Followed by Sphincter Preservation for Rectal Cancer: Increased Local Failure Rate in Nonresponders. Clinical Colorectal Cancer, 2006, 5, 413-421.	2.3	15
297	Biomarkers in colorectal cancer: added value or just added expense?. Expert Review of Molecular Diagnostics, 2008, 8, 231-233.	3.1	15
298	Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1227-1230.	2.5	15
299	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. European Journal of Cancer, 2020, 130, 63-71.	2.8	15
300	p27Kip1 in Stage III Colon Cancer: Implications for Outcome following Adjuvant Chemotherapy in Cancer and Leukemia Group B Protocol 89803. Clinical Cancer Research, 2009, 15, 2116-2122.	7.0	14
301	Biopsy and Margins Optimize Outcomes after Thermal Ablation of Colorectal Liver Metastases. Cancers, 2022, 14, 693.	3.7	14
302	ACR Appropriateness Criteria® on Treatment of Anal Cancer. Journal of the American College of Radiology, 2007, 4, 448-456.	1.8	13
303	A Phase II Study of Topotecan Administered Five Times Daily in Patients with Advanced Gastric Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1997, 20, 621-625.	1.3	13
304	A phase I trial of intrahepatic Verapamil and doxorubicin. Regional therapy to overcome multidrug resistance. Cancer, 1994, 74, 2757-2764.	4.1	12
305	Phase II clinical trial of 13-cis-retinoic acid and interferon-?-2a in patients with advanced esophageal carcinoma. , 1999, 85, 1213-1217.		12
306	A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum. Investigational New Drugs, 2004, 22, 53-61.	2.6	12

f

#	Article	IF	CITATIONS
307	ACR Appropriateness Criteria®: Local Excision in Early-Stage Rectal Cancer. Current Problems in Cancer, 2010, 34, 193-200.	2.0	12
308	Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. Oncologist, 2022, 27, 380-388.	3.7	12
309	Adjuvant Chemotherapy of Colorectal Cancer. Oncologist, 1996, 1, 22-29.	3.7	11
310	ACR Appropriateness Criteria®: Rectal Cancer—Metastatic Disease at Presentation. Current Problems in Cancer, 2010, 34, 201-210.	2.0	11
311	Hospitalists on an Inpatient Tertiary Care Oncology Teaching Service. Journal of Oncology Practice, 2015, 11, e114-e119.	2.5	11
312	Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population. Annals of Oncology, 2015, 26, 950-958.	1.2	11
313	Clinical Use of Irinotecan:Current Status and Future Considerations. Oncologist, 1997, 2, 402-409.	3.7	11
314	30-Day-or-Sooner Readmissions of Gastrointestinal Medical Oncology Patients Following Cancer Center Inpatient Service Discharge: Characteristics and Preventability. Hospital Practice, 2014, 42, 34-44.	0.5	11
315	Palliative management of rectal cancer: the roles of chemotherapy and radiation therapy. Journal of Gastrointestinal Surgery, 2004, 8, 274-276.	1.7	10
316	Assessing the Value of Next-Generation Sequencing Tests in a Dynamic Environment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 139-146.	3.8	10
317	Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). JNCI Cancer Spectrum, 2018, 2, pky017.	2.9	10
318	Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors. Clinical Cancer Research, 2020, 26, 1555-1562.	7.0	10
319	Colorectal Cancer Treatment: What's Next? (or: Is There Life After EGFR and VEGF?). Gastrointestinal Cancer Research: GCR, 2008, 2, S20-2.	0.7	10
320	A phase I trial of a modified, dose intensive FAMTX regimen (High dose 5-fluorouracil + doxorubicin +) Tj ETQqC	0 0 0 rgBT /	Overlock 10 ⁻
321	BRAF Mutations in Colorectal Cancer: Clinical Relevance and Role in Targeted Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1456-1458.	4.9	9
322	Role of Expression Profiling in Carcinoma of Unknown Primary Remains Unknown. Journal of Clinical Oncology, 2013, 31, 2513-2514.	1.6	9
323	Systemic Therapy for Metastatic Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 649-652.	4.9	9

³²⁴Assessment of Clinical Complete Response After Chemoradiation for Rectal Cancer with Digital Rectal
Examination, Endoscopy, and MRI. Annals of Surgical Oncology, 2015, 22, 3769-3771.1.59

#	Article	IF	CITATIONS
325	Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. Journal of Geriatric Oncology, 2016, 7, 422-429.	1.0	9
326	Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer. Journal of the National Cancer Institute, 2017, 109, .	6.3	9
327	Pelvic MRI after induction chemotherapy and before long-course chemoradiation therapy for rectal cancer: What are the imaging findings?. European Radiology, 2019, 29, 1733-1742.	4.5	9
328	Understanding the Right to Try Act. Clinical Cancer Research, 2020, 26, 340-343.	7.0	9
329	Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer (CRC): An analysis of 18,399 patients in the ARCAD database Journal of Clinical Oncology, 2020, 38, 4029-4029.	1.6	9
330	Drug Treatment of Colorectal Cancer. Drugs, 1991, 42, 616-627.	10.9	8
331	Another Study of How to Give Fluorouracil?. Journal of Clinical Oncology, 2003, 21, 3711-3712.	1.6	8
332	Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?. Nature Clinical Practice Oncology, 2005, 2, 20-21.	4.3	8
333	Targeted Strategies in the Treatment of Metastatic Colon Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, 983-990.	4.9	8
334	Axillary Lymph Node Involvement, a Unique Pattern of Metastasis in <i>BRAF</i> -Mutant Colorectal Cancer. JAMA Oncology, 2015, 1, 686.	7.1	8
335	Bevacizumab in colorectal cancer: it should have worked. Lancet Oncology, The, 2016, 17, 1469-1470.	10.7	8
336	Outcomes of ICU Admission of Patients With Progressive Metastatic Gastrointestinal Cancer. Journal of Intensive Care Medicine, 2020, 35, 297-302.	2.8	8
337	Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer. Anti-Cancer Drugs, 2004, 15, 219-227.	1.4	7
338	ACR Appropriateness Criteria on Resectable Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1427-1430.	0.8	7
339	Value in Colorectal Cancer Treatment. Cancer Journal (Sudbury, Mass), 2016, 22, 232-235.	2.0	7
340	Recommendations for Testing and Treating Outpatient Cancer Patients in the Era of COVID-19. Journal of the National Cancer Institute, 2021, 113, 820-822.	6.3	7
341	Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer Journal of Clinical Oncology, 2022, 40, LBA5-LBA5.	1.6	7
342	A phase I trial of cisplatin in hypertonic saline and escalating doses of 5-fluorouracil by continuous intravenous infusion in patients with advanced malignancies. Cancer, 1990, 66, 1688-1691.	4.1	6

#	Article	IF	CITATIONS
343	The role of irinotecan in colorectal cancer. Current Oncology Reports, 1999, 1, 155-160.	4.0	6
344	First-Line Treatment of Patients with Metastatic Colorectal Cancer: An Overview of Recent Data on Chemotherapy plus Targeted Agents. Clinical Colorectal Cancer, 2008, 7, S47-S51.	2.3	6
345	Doxorubicin and Sorafenib for Treatment of Advanced Hepatocellular Cancer. Gastroenterology, 2011, 141, e19-e20.	1.3	6
346	Phase I Study of Two Schedules of Oral S-1 in Combination with Fixed Doses of Oxaliplatin and Bevacizumab in Patients with Advanced Solid Tumors. Oncology, 2011, 81, 65-72.	1.9	6
347	Translational Considerations on the Outlook of Immunotherapy for Colorectal Cancer. Current Colorectal Cancer Reports, 2015, 11, 92-97.	0.5	6
348	Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. JAMA Network Open, 2019, 2, e1911750.	5.9	6
349	The Landmark Series: Chemotherapy for Non-Metastatic Colon Cancer. Annals of Surgical Oncology, 2021, 28, 995-1001.	1.5	6
350	Surgical Debulking and Intraperitoneal Chemotherapy for Established Peritoneal Metastases From Colon and Appendix Cancer. Annals of Surgical Oncology, 2001, 8, 787-795.	1.5	6
351	Anal Canal Cancer Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2003, 1, 64.	4.9	6
352	Planned Treatment Interruptions and Chemotherapy-Free Intervals in the Treatment of Metastatic Colorectal Cancer: Time to Start Stopping?. Seminars in Oncology, 2006, 33, 28-32.	2.2	5
353	Is adjuvant therapy for stage II colon cancer worthwhile, and for whom?. Nature Reviews Gastroenterology & Hepatology, 2008, 5, 422-423.	1.7	5
354	Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a ¹ H MRS study. NMR in Biomedicine, 2013, 26, 204-212.	2.8	5
355	Value-Added Decisions in Oncology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 122-131.	3.8	5
356	The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance). Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1692-1695.	2.5	5
357	Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. Journal of the National Cancer Institute, 2022, 114, 60-67.	6.3	5
358	Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance). Oncologist, 2022, 27, e494-e505.	3.7	5
359	The Hardest Weeks of My Life: A Qualitative Study of Experiences, Practice Changes, and Emotional Burden of New York City Oncology Physicians During the COVID-19 Surge in 2020. JCO Oncology Practice, 2022, 18, e669-e676.	2.9	5
360	Top advances of the year in colorectal cancer. Cancer, 2022, 128, 2236-2239.	4.1	5

#	Article	IF	CITATIONS
361	Irinotecan: A New Agent Comes of Age. Oncologist, 2001, 6, 65-65.	3.7	4
362	Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer. Investigational New Drugs, 2009, 27, 366-373.	2.6	4
363	Antitumor Activity in Metastatic Disease Does Not Predict Efficacy in the Adjuvant Setting. JAMA - Journal of the American Medical Association, 2012, 307, 1431.	7.4	4
364	Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802). Journal of Geriatric Oncology, 2014, 5, 230-237.	1.0	4
365	The Cost and Value of Anti–Epidermal Growth Factor Receptor Therapies. JAMA Oncology, 2015, 1, 141.	7.1	4
366	Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m ² /min. Journal of Oncology Practice, 2016, 12, e548-e553.	2.5	4
367	Discharge to Subacute Rehabilitation Facilities Does Not Benefit Patients Hospitalized With Progressive Gastrointestinal Cancer. Journal of Pain and Symptom Management, 2017, 54, e4-e7.	1.2	4
368	First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors. Investigational New Drugs, 2018, 36, 860-868.	2.6	4
369	Can We Afford That CAR? Confronting the Effect of Novel Immunotherapies on Future Health Care Costs. Journal of Clinical Oncology, 2018, 36, 1381-1382.	1.6	4
370	Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). JNCI Cancer Spectrum, 2021, 5, pkab034.	2.9	4
371	Clinical Use of Irinotecan: Current Status and Future Considerations. Oncologist, 1997, 2, 402-409.	3.7	4
372	BEYOND KRAS: Other Markers and Potential Treatment Strategies for KRAS Mutant and Wild-type Patients. Current Treatment Options in Oncology, 2011, 12, 126-135.	3.0	3
373	RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Response. Clinical Cancer Research, 2015, 21, 2188-2188.	7.0	3
374	Precision oncology giveth and precision oncology taketh away. Lancet Oncology, The, 2019, 20, 464-466.	10.7	3
375	Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer. Clinical Colorectal Cancer, 2019, 18, 167-174.	2.3	3
376	Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials. Clinical Trials, 2021, 18, 51-60.	1.6	3
377	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110205.	3.2	3
378	In Defense of TNT: A Dynamite Strategy. Journal of Clinical Oncology, 2021, 39, 1185-1186.	1.6	3

#	Article	IF	CITATIONS
379	Total neoadjuvant therapy for locally advanced rectal cancer Journal of Clinical Oncology, 2017, 35, 662-662.	1.6	3
380	A phase II study of induction PD-1 blockade in subjects with locally advanced mismatch repair-deficient rectal adenocarcinoma Journal of Clinical Oncology, 2020, 38, TPS4123-TPS4123.	1.6	3
381	Radical Resection of Rectal Cancer Primary Tumor Provides Effective Local Therapy in Patients With Stage IV Disease. Annals of Surgical Oncology, 2002, 9, 954-960.	1.5	3
382	Looking ahead: what will change in colorectal cancer treatment?. Gastrointestinal Cancer Research: GCR, 2009, 3, S16-8.	0.7	3
383	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. JNCI Cancer Spectrum, 2022, 6, .	2.9	3
384	Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer. JAMA Network Open, 2022, 5, e220145.	5.9	3
385	Factors Dictating Outcomes in Patients With Colorectal Cancer and Peritoneal Carcinomatosis: Selection, Resection, or Convection?. Journal of Clinical Oncology, 2012, 30, 226-228.	1.6	2
386	Genetic Screening in All Young Patients With Colorectal Cancer?. Journal of Clinical Oncology, 2016, 34, 1560-1560.	1.6	2
387	Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer, 1999, 86, 944-948.	4.1	2
388	Curative-Intent Treatment for Colorectal Liver Metastases: A Medical Oncologist's Perspective. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 205-208.	3.8	2
389	Occult Primary. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 1026.	4.9	2
390	Management of a patient diagnosed with pancreatic cancer and myelodysplastic syndrome. Gastrointestinal Cancer Research: GCR, 2013, 6, 56-60.	0.7	2
391	Simplified Graded Infusion Strategy for Mitigation of Oxaliplatin Hypersensitivity. Clinical Colorectal Cancer, 2022, , .	2.3	2
392	A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors. JCO Oncology Practice, 2022, 18, e1533-e1541.	2.9	2
393	Phase I trial of pre-operative combined radiation therapy, 5-FU, and low dose leucovorin for unresectable rectar cancer. International Journal of Radiation Oncology Biology Physics, 1992, 24, 248.	0.8	1
394	Size Matters. Oncology Research and Treatment, 2007, 30, 167-167.	1.2	1
395	Targeted therapy for metastatic colorectal cancer: Current challenges and future directions. Current Colorectal Cancer Reports, 2007, 3, 109-115.	0.5	1
396	Association of Dietary Patterns With Cancer Recurrence and Survival in Patients With Stage III Colon Cancer. Obstetrical and Gynecological Survey, 2008, 63, 94-96.	0.4	1

#	Article	IF	CITATIONS
397	Phase I Study of Weekly Cisplatin, Bolus Fluorouracil and Escalating Doses of Irinotecan in Advanced Solid Tumors. Cancer Investigation, 2009, 27, 402-406.	1.3	1
398	Treatment Options for Patients With Unresectable Colorectal Cancer With Wild-Type KRAS. Current Colorectal Cancer Reports, 2012, 8, 170-176.	0.5	1
399	Biologic agents in the treatment of colorectal cancer: an update. Colorectal Cancer, 2014, 3, 363-374.	0.8	1
400	Genomic Profiling of Cancers of Unknown Primary Site. JAMA Oncology, 2015, 1, 541.	7.1	1
401	Colorectal Cancer. Hematology/Oncology Clinics of North America, 2015, 29, ix.	2.2	1
402	Commentary: Somatostatin analogsâ \in "How we choose, and why. Seminars in Oncology, 2017, 44, 157-158.	2.2	1
403	Reply to S. Boutayeb et al. JCO Oncology Practice, 2020, 16, 525-525.	2.9	1
404	The rate and risk of secondary pelvic malignancies (SPM) in patients treated with definitive radiation for locally advanced rectal cancer Journal of Clinical Oncology, 2021, 39, 12065-12065.	1.6	1
405	Biologic Agents in the Treatment of Colorectal Cancer: The Last Decade; the Lost Decade?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e121-e125.	3.8	1
406	Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database Journal of Clinical Oncology, 2020, 38, 4099-4099.	1.6	1
407	Second- and third-line treatment options for unresectable metastatic colorectal cancer. Gastrointestinal Cancer Research: GCR, 2008, 2, 299-302.	0.7	1
408	A 40-year-old woman with locally advanced rectal cancer and a solitary liver metastasis. Gastrointestinal Cancer Research: GCR, 2013, 6, 87-9.	0.7	1
409	A 39-year-old female patient with metastatic rectal cancer develops thrombocytopenia. Gastrointestinal Cancer Research: GCR, 2014, 7, 55-8.	0.7	1
410	Liver-directed conversion therapy in metastatic colon cancer. Journal of Gastrointestinal Oncology, 2015, 6, 322-8.	1.4	1
411	Current role of bevacizumab in colorectal cancer. Clinical Advances in Hematology and Oncology, 2009, 7, 375-6.	0.3	1
412	Peripheral Neuroectodermal Tumor-Ewing's Sarcoma of the Thumb With Local Recurrences and Pleural Metastases After 17 Years. International Journal of Surgical Pathology, 1994, 2, 147-156.	0.8	0
413	Author reply. , 2000, 88, 2195-2195.		0
414	Recommendation for Irinotecan, 5-Fluorouracil, and Leucovorin as First-Line Therapy for Colorectal Cancer. Clinical Colorectal Cancer, 2001, 1, 82-84.	2.3	0

#	Article	IF	CITATIONS
415	Capecitabine monotherapy in metastatic colorectal cancer – Authors' reply. Lancet Oncology, The, 2001, 2, 400.	10.7	0
416	Irinotecan in the Treatment of Colorectal Cancer. , 2002, , 513-524.		0
417	Unusual Tumors of the Colon, Rectum and Anus. , 2006, , 401-409.		0
418	Oxaliplatin and irinotecan: From advanced to adjuvant therapy of colon cancer. Current Colorectal Cancer Reports, 2006, 2, 142-148.	0.5	0
419	Apples and oranges: the low and mid versus the upper rectum. Nature Reviews Clinical Oncology, 2009, 6, 385-386.	27.6	0
420	Evaluation of Bevacizumab in the Adjuvant Treatment of Colon Cancer. Current Colorectal Cancer Reports, 2010, 6, 109-110.	0.5	0
421	PD-0009 Primary Tumor Location is a Major Independent Prognostic Factor for Mcrc Patients. Annals of Oncology, 2012, 23, iv22.	1.2	0
422	Use of Chemotherapy in the Resection of Liver Metastases of Colorectal Cancer. Current Colorectal Cancer Reports, 2013, 9, 178-184.	0.5	0
423	Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al. Journal of Clinical Oncology, 2015, 33, 3843-3844.	1.6	0
424	An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses. Journal of Gastrointestinal Oncology, 2017, 8, 596-602.	1.4	0
425	Author's Response. Journal of Pain and Symptom Management, 2018, 55, e2-e3.	1.2	0
426	Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer. Leukemia Research, 2019, 82, 19-23.	0.8	0
427	Lack of Availability and Efficacy of Phase I and Basket Trials for Patients With Gastrointestinal Cancers. Journal of the National Cancer Institute, 2020, 112, 438-442.	6.3	0
428	Clinicopathological and molecular characteristics of early-onset stage III colon adenocarcinoma: An analysis of 25 studies with 35,713 patients in the Adjuvant Colon Cancer End Points (ACCENT) database Journal of Clinical Oncology, 2021, 39, 3597-3597.	1.6	0
429	Randomized blinded study comparing injection site pain from octreotide long-acting-release (LAR) versus lanreotide during the treatment of well differentiated neuroendocrine tumors (WDNETs) Journal of Clinical Oncology, 2021, 39, e16204-e16204.	1.6	0
430	Adjuvant Therapy for Colon Cancer. , 2002, , 585-596.		0
431	Advances in systemic therapy for hepatocellular carcinoma. , 2012, , 1444-1452.e3.		0

Adenocarcinoma of the Colon and Rectum. , 2013, , 2051-2074.

#	Article	IF	CITATIONS
433	Clinical Use of Camptosar (CPTâ€11). Oncologist, 1997, 2, 191-191.	3.7	Ο
434	Actionable alterations (AA) in gastrointestinal (GI) cancers: Rate of detection and receipt of matched therapies (MT) Journal of Clinical Oncology, 2020, 38, e15677-e15677.	1.6	0
435	Immediate post-thermal ablation biopsy of colorectal liver metastases to predict oncologic outcomes Journal of Clinical Oncology, 2020, 38, 4602-4602.	1.6	Ο
436	Survival outcomes among older adults (OA) receiving second-line therapy for metastatic CRC (mCRC): 5,289 patients (pts) from the ARCAD Clinical Trials Program Journal of Clinical Oncology, 2020, 38, 7009-7009.	1.6	0
437	Combination chemotherapy: the fallback position?. Gastrointestinal Cancer Research: GCR, 2008, 2, 154-5.	0.7	Ο
438	Neoadjuvant Therapy in Clinical Stage II Pancreatic Adenocarcinoma. Gastrointestinal Cancer Research: GCR, 2012, 5, 169-73.	0.7	0
439	Modified GTX as Second-Line Chemotherapy in Advanced Pancreatic Cancer. Gastrointestinal Cancer Research: GCR, 2013, 6, 115-7.	0.7	0
440	Efficacy of bevacizumab-based treatment in early-onset treatment-naÃ ⁻ ve metastatic colorectal cancer patients: An ARCAD database analysis Journal of Clinical Oncology, 2022, 40, 101-101.	1.6	0